{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:33:44Z","timestamp":1793392424923,"version":"4.5.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"vor","delay-in-days":28,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline Plc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jaip.2025.04.007","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T11:19:52Z","timestamp":1744370392000},"page":"1559-1568","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Asthma in the Biologics Era: Should Oral Corticosteroid Therapy Be Relegated to History?"],"prefix":"10.1016","volume":"13","author":[{"given":"Florence","family":"Schleich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Oppenheimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Brusselle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liam G.","family":"Heaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William W.","family":"Busse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Njira L.","family":"Lugogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola A.","family":"Hanania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Lommatzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Chanez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Vichiendilokkul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria S.","family":"Benson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tricia","family":"Finney-Hayward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Howarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliot","family":"Israel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5 suppl 68","key":"10.1016\/j.jaip.2025.04.007_bib1","article-title":"History of the development of corticosteroid therapy","volume":"29","author":"Benedek","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jaip.2025.04.007_bib2","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3390\/jpm12030504","article-title":"Reducing tolerance for SABA and OCS towards the extreme ends of asthma severity","volume":"12","author":"Bakakos","year":"2022","journal-title":"J Pers Med"},{"key":"10.1016\/j.jaip.2025.04.007_bib4","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jaci.2020.10.003","article-title":"2020 focused updates to the Asthma Management Guidelines: a report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group","volume":"146","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.04.007_bib5","first-page":"53","article-title":"Trends in systemic glucocorticoid utilization in the United Kingdom from 1990 to 2019: a population-based, serial cross-sectional analysis","volume":"15","author":"Menzies-Gow","year":"2024","journal-title":"Pragmat Obs Res"},{"key":"10.1016\/j.jaip.2025.04.007_bib6","series-title":"Inhaled corticosteroids. StatPearls. Treasure Island, FL","author":"Liang","year":"2023"},{"key":"10.1016\/j.jaip.2025.04.007_bib7","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJM195304162481604","article-title":"The role of cortisone in the treatment of severe bronchial asthma","volume":"248","author":"Burrage","year":"1953","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.04.007_bib8","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1164\/rccm.201904-0903SO","article-title":"Systematic literature review of systemic corticosteroid use for asthma management","volume":"201","author":"Bleecker","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2025.04.007_bib9","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12931-018-0742-y","article-title":"Adverse events profile of oral corticosteroids among asthma patients in the UK: cohort study with a nested case-control analysis","volume":"19","author":"Bloechliger","year":"2018","journal-title":"Respir Res"},{"key":"10.1016\/j.jaip.2025.04.007_bib10","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1007\/s12325-023-02479-0","article-title":"A charter to fundamentally change the role of oral corticosteroids in the management of asthma","volume":"40","author":"Haughney","year":"2023","journal-title":"Adv Ther"},{"key":"10.1016\/j.jaip.2025.04.007_bib11","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2147\/JAA.S176026","article-title":"Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study","volume":"11","author":"Price","year":"2018","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.jaip.2025.04.007_bib12","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0140-6736(58)91385-0","article-title":"Treatment of chronic asthma with prednisolone; significance of eosinophils in the sputum","volume":"2","author":"Brown","year":"1958","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2025.04.007_bib13","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1136\/bmj.2.5264.1396","article-title":"Difficulties in weaning in steroid treatment in asthma","volume":"2","author":"Knowles","year":"1961","journal-title":"Br Med J"},{"key":"10.1016\/j.jaip.2025.04.007_bib14","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.jaip.2021.12.027","article-title":"Global variability in administrative approval prescription criteria for biologic therapy in severe asthma","volume":"10","author":"Porsbjerg","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.04.007_bib15","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2025.04.007_bib16","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.04.007_bib17","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.04.007_bib18","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.04.007_bib19","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJMra2032506","article-title":"Biologic therapies for severe asthma","volume":"386","author":"Brusselle","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.04.007_bib20","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.anai.2023.11.006","article-title":"Real-world effectiveness of dupilumab in patients with asthma: findings from the US ADVANTAGE study","volume":"132","author":"Blaiss","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2025.04.007_bib21","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1710-1492-9-47","article-title":"Reduction in oral corticosteroid use in patients receiving omalizumab for allergic asthma in the real-world setting","volume":"9","author":"Braunstahl","year":"2013","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaip.2025.04.007_bib22","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.anai.2022.02.017","article-title":"Real-world effectiveness of benralizumab: results from the ZEPHYR 1 Study","volume":"128","author":"Chung","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2025.04.007_bib23","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/j.jaip.2022.04.014","article-title":"Real-world effectiveness of reslizumab in patients with severe eosinophilic asthma - first initiators and switchers","volume":"10","author":"Hashimoto","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.04.007_bib24","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1016\/j.jaip.2022.05.042","article-title":"REALITI-A study: real-world oral corticosteroid-sparing effect of mepolizumab in severe asthma","volume":"10","author":"Pilette","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.04.007_bib25","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S2213-2600(21)00537-3","article-title":"Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study","volume":"10","author":"Wechsler","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2025.04.007_bib26","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jaip.2021.09.023","article-title":"Anti-interleukin-5 therapy is associated with attenuated lung function decline in severe eosinophilic asthma patients from the Belgian Severe Asthma Registry","volume":"10","author":"Graff","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.04.007_bib27","series-title":"Poster PA1175 presented at the European Respiratory Society Congress","article-title":"Has OCS use for severe asthma in the US decreased in the last 10 years?","author":"Benson","year":"2024"},{"key":"10.1016\/j.jaip.2025.04.007_bib28","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jaci.2019.12.006","article-title":"An expert consensus framework for asthma remission as a treatment goal","volume":"145","author":"Menzies-Gow","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.04.007_bib29","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/resp.13730","article-title":"Rational oral corticosteroid use in adult severe asthma: a narrative review","volume":"25","author":"Chung","year":"2020","journal-title":"Respirology"},{"key":"10.1016\/j.jaip.2025.04.007_bib30","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0183-2021","article-title":"Holy Grail: the journey towards disease modification in asthma","volume":"31","author":"Busse","year":"2022","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.jaip.2025.04.007_bib31","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.jaci.2021.01.029","article-title":"Quantitative CT metrics are associated with longitudinal lung function decline and future asthma exacerbations: results from SARP-3","volume":"148","author":"Krings","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.04.007_bib32","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1136\/thorax-2021-217032","article-title":"Asthma exacerbations are associated with a decline in lung function: a longitudinal population-based study","volume":"78","author":"Soremekun","year":"2023","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2025.04.007_bib33","article-title":"Longitudinal patterns of intermittent oral corticosteroid therapy for asthma in the United Kingdom","volume":"3","author":"Tran","year":"2024","journal-title":"J Allergy Clin Immunol Glob"},{"key":"10.1016\/j.jaip.2025.04.007_bib34","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/resp.14533","article-title":"The burden of systemic corticosteroid use in asthma management in Asia","volume":"28","author":"Dhar","year":"2023","journal-title":"Respirology"},{"key":"10.1016\/j.jaip.2025.04.007_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2023.100760","article-title":"The use of systemic corticosteroids in asthma management in Latin American countries","volume":"16","author":"Maspero","year":"2023","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jaip.2025.04.007_bib36","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01163-2019","article-title":"Characteristics and treatment regimens across ERS SHARP severe asthma registries","volume":"55","author":"van Bragt","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2025.04.007_bib38","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1136\/thoraxjnl-2020-215168","article-title":"Characterisation of patients with severe asthma in the UK Severe Asthma Registry in the biologic era","volume":"76","author":"Jackson","year":"2021","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2025.04.007_bib39","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00819-2023","article-title":"Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry","volume":"62","author":"McDowell","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2025.04.007_bib40","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0132-2021","article-title":"ERS\/EAACI statement on adherence to international adult asthma guidelines","volume":"30","author":"Mathioudakis","year":"2021","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.jaip.2025.04.007_bib41","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/joim.13273","article-title":"Long-term corticosteroid use, adrenal insufficiency and the need for steroid-sparing treatment in adult severe asthma","volume":"290","author":"Gurnell","year":"2021","journal-title":"J Intern Med"},{"key":"10.1016\/j.jaip.2025.04.007_bib42","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S2213-2600(21)00352-0","article-title":"Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study","volume":"10","author":"Menzies-Gow","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2025.04.007_bib43","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.03226-2021","article-title":"Adrenal function recovery after durable oral corticosteroid sparing with benralizumab in the PONENTE study","volume":"60","author":"Menzies-Gow","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2025.04.007_bib44","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0238-2023","article-title":"Biologic agents licensed for severe asthma: a systematic review and meta-analysis of randomised controlled trials","volume":"33","author":"Kyriakopoulos","year":"2024","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.jaip.2025.04.007_bib45","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/cea.13601","article-title":"Real-word experience with mepolizumab: does it deliver what it has promised?","volume":"50","author":"Schleich","year":"2020","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2025.04.007_bib46","doi-asserted-by":"crossref","first-page":"00383","DOI":"10.1183\/23120541.00383-2023","article-title":"Benralizumab in severe eosinophilic asthma in real life: confirmed effectiveness and contrasted effect on sputum eosinophilia versus exhaled nitric oxide fraction - PROMISE","volume":"9","author":"Schleich","year":"2023","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jaip.2025.04.007_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2021.100528","article-title":"\"Real-life\" management of patients with severe asthma in the biologics era: can we do better?","volume":"14","author":"Charriot","year":"2021","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jaip.2025.04.007_bib48","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.anai.2024.03.009","article-title":"Activated non-neuronal cholinergic system correlates with non-type 2 inflammation and exacerbations in severe asthma","volume":"133","author":"Huang","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2025.04.007_bib49","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S2213-2600(21)00004-7","article-title":"The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study","volume":"9","author":"McDowell","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2025.04.007_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2021.135795","article-title":"Mini review: Neural mechanisms underlying airway hyperresponsiveness","volume":"751","author":"Pincus","year":"2021","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.jaip.2025.04.007_bib51","doi-asserted-by":"crossref","DOI":"10.20452\/pamw.16250","article-title":"Asthma and comorbidities: recent advances","volume":"132","author":"Cazzola","year":"2022","journal-title":"Pol Arch Intern Med"},{"key":"10.1016\/j.jaip.2025.04.007_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4193\/Rhin20.401","article-title":"European Position Paper on Rhinosinusitis and Nasal Polyps 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"key":"10.1016\/j.jaip.2025.04.007_bib53","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1016\/j.jaip.2022.05.031","article-title":"The contribution of oral and inhaled glucocorticoids to adrenal insufficiency in asthma","volume":"10","author":"Brennan","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.04.007_bib54","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaci.2017.04.009","article-title":"Oral corticosteroid exposure and adverse effects in asthmatic patients","volume":"141","author":"Sullivan","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.04.007_bib55","article-title":"Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study","volume":"357","author":"Waljee","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.jaip.2025.04.007_bib56","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0140-6736(22)00331-2","article-title":"Disease-modifying anti-asthmatic drugs","volume":"399","author":"Lommatzsch","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2025.04.007_bib57","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.anai.2023.08.609","article-title":"Consensus of an American College of Allergy, Asthma, and Immunology, American Academy of Allergy, Asthma, and Immunology, and American Thoracic Society workgroup on definition of clinical remission in asthma on treatment","volume":"131","author":"Blaiss","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2025.04.007_bib58","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S2213-2600(23)00415-0","article-title":"Pioneering a paradigm shift in asthma management: remission as a treatment goal","volume":"12","author":"Lommatzsch","year":"2024","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2025.04.007_bib59","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2147\/JAA.S178927","article-title":"Approaches to the assessment of severe asthma: barriers and strategies","volume":"12","author":"Majellano","year":"2019","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.jaip.2025.04.007_bib60","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.chest.2023.01.037","article-title":"Sputum type 2 markers could predict remission in severe asthma treated with anti-IL-5","volume":"163","author":"Moermans","year":"2023","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2025.04.007_bib61","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S2213-2600(24)00293-5","article-title":"Clinical remission attainment, definitions, and correlates among patients with severe asthma treated with biologics: a systematic review and meta-analysis","volume":"13","author":"Shackleford","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2025.04.007_bib62","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.chest.2023.10.046","article-title":"Clinical response and remission in patients with severe asthma treated with biologic therapies","volume":"165","author":"Hansen","year":"2024","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2025.04.007_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.152010","article-title":"The glucocorticoid toxicity index: measuring change in glucocorticoid toxicity over time","volume":"55","author":"Stone","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jaip.2025.04.007_bib64","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jaip.2024.10.024","article-title":"Longitudinal assessment of glucocorticoid toxicity reduction in patients with severe asthma treated with biologic therapies","volume":"13","author":"McDowell","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.04.007_bib65","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00160-2021","article-title":"Glucocorticoid toxicity reduction with mepolizumab using the Glucocorticoid Toxicity Index","volume":"59","author":"McDowell","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2025.04.007_bib66","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1164\/rccm.202311-2192OC","article-title":"Exploring definitions and predictors of severe asthma clinical remission after biologic treatment in adults","volume":"210","author":"Perez-de-Llano","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2025.04.007_bib67","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.anai.2017.02.023","article-title":"Cost and health care utilization in patients with asthma and high oral corticosteroid use","volume":"118","author":"Broder","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2025.04.007_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2022.100726","article-title":"Systemic corticosteroids in asthma: a call to action from World Allergy Organization and Respiratory Effectiveness Group","volume":"15","author":"Bleecker","year":"2022","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jaip.2025.04.007_bib69","doi-asserted-by":"crossref","first-page":"7132","DOI":"10.3390\/ijms22137132","article-title":"Oral corticosteroids dependence and biologic drugs in severe asthma: myths or facts? A systematic review of real-world evidence","volume":"22","author":"Calzetta","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaip.2025.04.007_bib70","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1080\/02770903.2019.1705335","article-title":"Severe asthma: oral corticosteroid alternatives and the need for optimal referral pathways","volume":"58","author":"Cataldo","year":"2021","journal-title":"J Asthma"},{"key":"10.1016\/j.jaip.2025.04.007_bib71","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.chest.2022.04.004","article-title":"Are we poised to change the trajectory of maintenance oral corticosteroid use in severe asthma in the age of biologics?","volume":"162","author":"Lugogo","year":"2022","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2025.04.007_bib72","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1164\/rccm.202007-2721OC","article-title":"Expert consensus on the tapering of oral corticosteroids for the treatment of asthma. A Delphi study","volume":"203","author":"Suehs","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2025.04.007_bib73","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1183\/13993003.01359-2015","article-title":"Treatable traits: toward precision medicine of chronic airway diseases","volume":"47","author":"Agusti","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2025.04.007_bib74","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S2213-2600(20)30397-0","article-title":"Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial","volume":"9","author":"Heaney","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2025.04.007_bib75","doi-asserted-by":"crossref","first-page":"565","DOI":"10.2217\/pme.13.57","article-title":"P4 medicine: how systems medicine will transform the healthcare sector and society","volume":"10","author":"Flores","year":"2013","journal-title":"Per Med"},{"key":"10.1016\/j.jaip.2025.04.007_bib76","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s40521-023-00330-z","article-title":"Asthma exacerbations in severe asthma: why systemic corticosteroids may not always be the best treatment option","volume":"10","author":"McDowell","year":"2023","journal-title":"Curr Treat Options Allergy"},{"key":"10.1016\/j.jaip.2025.04.007_bib77","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1164\/rccm.202201-0129OC","article-title":"Exacerbation profile and risk factors in a type-2-low enriched severe asthma cohort: a clinical trial to assess asthma exacerbation phenotypes","volume":"206","author":"McDowell","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2025.04.007_bib78","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12931-022-01959-1","article-title":"Development of methodology for assessing steroid-tapering in clinical trials for biologics in asthma","volume":"23","author":"Korn","year":"2022","journal-title":"Respir Res"},{"key":"10.1016\/j.jaip.2025.04.007_bib79","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S2213-2600(24)00304-7","article-title":"Asthma remission: a call for a globally standardised definition","volume":"13","author":"Lommatzsch","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2025.04.007_bib80","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2025.04.007_bib81","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2025.04.007_bib82","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-154-9-201105030-00002","article-title":"Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial","volume":"154","author":"Hanania","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaip.2025.04.007_bib83","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1398-9995.2004.00772.x","article-title":"Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE","volume":"60","author":"Humbert","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.04.007_bib84","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.04.007_bib85","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/all.15056","article-title":"From DREAM to REALITI-A and beyond: mepolizumab for the treatment of eosinophil-driven diseases","volume":"77","author":"Pavord","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.04.007_bib86","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jaci.2018.09.033","article-title":"Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma","volume":"143","author":"Khatri","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.04.007_bib87","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1016\/j.jaip.2021.07.058","article-title":"Integrated safety and efficacy among patients receiving benralizumab for up to 5 years","volume":"9","author":"Korn","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.04.007_bib88","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.jaip.2023.12.043","article-title":"Long-term safety of dupilumab in patients with moderate-to-severe asthma: TRAVERSE continuation study","volume":"12","author":"Maspero","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.04.007_bib89","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2147\/JAA.S363398","article-title":"Efficacy and safety of omalizumab treatment over a 16-year follow-up: when a clinical trial meets real-life","volume":"15","author":"Menzella","year":"2022","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.jaip.2025.04.007_bib90","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S2213-2600(22)00492-1","article-title":"Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study","volume":"11","author":"Menzies-Gow","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2025.04.007_bib91","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.jaip.2017.08.024","article-title":"Long-term safety and efficacy of reslizumab in patients with eosinophilic asthma","volume":"5","author":"Murphy","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.04.007_bib92","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1016\/j.jaip.2023.05.044","article-title":"Impact of initiating biologics in patients with severe asthma on long-term oral corticosteroids or frequent rescue steroids (GLITTER): data from the International Severe Asthma Registry","volume":"11","author":"Chen","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.04.007_bib93","doi-asserted-by":"crossref","first-page":"960","DOI":"10.3390\/biomedicines12050960","article-title":"Evaluation of clinical remission in best-performing severe asthmatic patients treated for three years with mepolizumab","volume":"12","author":"Bagnasc","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.jaip.2025.04.007_bib94","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s12325-018-0777-y","article-title":"A charter to improve patient care in severe asthma","volume":"35","author":"Menzies-Gow","year":"2018","journal-title":"Adv Ther"},{"key":"10.1016\/j.jaip.2025.04.007_bib95","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1007\/s12325-022-02340-w","article-title":"A renewed charter: key principles to improve patient care in severe asthma","volume":"39","author":"Menzies-Gow","year":"2022","journal-title":"Adv Ther"},{"key":"10.1016\/j.jaip.2025.04.007_bib96","first-page":"A278","article-title":"M30 Accelerating access to specialist care for asthma patients through innovative pathway transformation","volume":"78","author":"Clarke","year":"2023","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2025.04.007_bib97","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1016\/j.jaip.2023.03.003","article-title":"Factors associated with asthma biologic prescribing and primary adherence among adults in a large health system","volume":"11","author":"Gleeson","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.04.007_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2024.107637","article-title":"Asthma patients' and physicians' perspectives on the burden and management of asthma: post-hoc analysis of APPaRENT 1 and 2 to assess predictors of treatment adherence","volume":"227","author":"Canonica","year":"2024","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2025.04.007_bib99","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S2213-2600(17)30124-8","article-title":"Managing asthma in the era of biological therapies","volume":"5","author":"Bardin","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2025.04.007_bib100","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1111\/all.15473","article-title":"Biologics and airway remodeling in severe asthma","volume":"77","author":"Varricchi","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.04.007_bib101","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1053\/j.gastro.2021.04.022","article-title":"AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn's disease","volume":"160","author":"Feuerstein","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaip.2025.04.007_bib102","doi-asserted-by":"crossref","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG clinical guideline: ulcerative colitis in adults","volume":"114","author":"Rubin","year":"2019","journal-title":"Am J Gastroenterol"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219825003599?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219825003599?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:40:24Z","timestamp":1755650424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219825003599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":100,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S2213219825003599"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2025.04.007","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Asthma in the Biologics Era: Should Oral Corticosteroid Therapy Be Relegated to History?","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2025.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}